Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Athiras lead clinical candidate, fosgonimeton (formerly ATH-1017 / NDX-1017), is a structurally distinct phosphate prodrug of Dihexa not Dihexa itself
About 10% of tirzepatide participants had a heart-rate increase above 20 bpm during escalation, compared with 3% on placebo. A lean Japanese cohort reached +10 to +13 bpm, and 23% of Japanese participants at 15 mg crossed the abnormal-pulse threshold versus 7% of other participants, despite only 17% higher exposure. Lean and East Asian bodies showed greater cardiovascular sensitivity than exposure alone predicted
Facts vs
Free UK Shipping on all orders over 30 Delivery options: Tracked 48: 3.98* Tracked 24: 4.67* Next Day Delivery: 6.96 Free UK Shipping on all orders over 30 Order cut-off is at 3:00pm Mon-Fri
,type=downsize)
